Designing Longevity
Skip to main content
Brand-name GLP-1

Hims & Hers

Public-company telehealth, post-settlement branded-only supply

Reviewed by Designing Longevity Editorial · last fact-checked May 1, 2026

3.4

out of 5

No financial relationship with Hims & Hers. Editorial inclusion only.

Visit Hims & Hers

Verdict in one glance

Best for

  • Users who specifically want branded Wegovy or Ozempic via telehealth

    Post-settlement Hims is an authorized Novo Nordisk distributor for branded injection, oral Wegovy pill, and . If you have eligible commercial insurance plus a Novo savings card, effective cost can land at $0-$25/month.

  • Users who specifically want the new oral Wegovy pill

    Oral was FDA-approved in early 2026 and is offered through Hims at $149/month medication cost (plus membership). Hims is one of the first telehealth channels with the pill.

  • Users who value public-company disclosure

    NYSE: HIMS means SEC filings, quarterly earnings, and audited financials. That is more visibility than any private competitor in our cohort offers.

Look elsewhere if

  • Cash-pay users on compounded GLP-1

    Per the March 2026 settlement, Hims has wound down . New patients without insurance who want compounded options should look at TrimRx or Eden instead.

  • Users sensitive to subscription billing friction

    and complaint patterns recurrently flag billing surprises, cancellation difficulty, and refund delays. Volume is high enough to count this as a known risk.

  • Users who want labs ordered before a GLP-1 prescription

    Hims uses async intake without baseline labs before prescribing. If you want pre-treatment labs, this is not the model.

Our take

If you specifically want a brand-name from a public-company telehealth platform with mature compliance infrastructure, post-settlement Hims is a credible option, especially for the new oral pill. The insurance pathway can drive Wegovy to $0-$25/month with eligible coverage. The honest counterweight: the September 2025 and the messy 2025 break with Novo Nordisk are both recent enough that we are docking the score below where a clean operator would land. at 3.0/5 with 28% one-star reviews is worse than Ro's, and the A+ does not fully offset that. For pure cash-pay GLP-1, Hims no longer competes (compounded is wound down post-settlement); look at TrimRx or Eden.

Pros

  • Public company (NYSE: HIMS) with SEC-grade financial disclosure
  • Accredited since 2018 with A+ rating, strongest in our cohort
  • Authorized distributor for Novo Nordisk , oral Wegovy pill, and post-settlement
  • Insurance + Novo savings card can drive to $0-$25/mo for eligible users
  • New oral pill (FDA-approved early 2026) available through Hims

Cons

  • Twin Sept 9, 2025 on - marketing claims
  • Messy 2025 break with Novo Nordisk over compounding before March 2026 settlement
  • 3.0/5 with 28% one-star reviews across roughly 8,000 reviews
  • Membership stack ($149/mo) is on top of medication cost
  • No option for new patients post-settlement
  • Async-only consultations; no labs ordered before prescribing

Pricing

$39 first month, $149/mo membership + $149-$299/mo medication

Turnaround

Same-day Rx after async intake

States served

All 50

Last verified

May 1, 2026

What Hims & Hers says, and what we found

The provider's own marketing claims, paired with our verdict. Color-coded so you can scan: green for verified, amber for stated-but-unconfirmed, violet for context.

VerifiedSourcing

Confirmed against the Hims newsroom post and Stat News reporting on the settlement. Per the deal, Hims agreed to make Novo branded priority offerings and to stop advertising GLP-1.

Hims is an authorized seller of injection, oral Wegovy pill, and following the March 2026 settlement with Novo Nordisk.

Hims newsroom · captured May 1, 2026 · source

VerifiedPricing

Confirmed. Worth flagging for users: the membership fee is separate from medication cost. and complaints frequently cite confusion when the medication price surfaces post-intake.

Hims weight-loss membership starts at $39 for the first month and is $149/month thereafter.

hims.com pricing page · captured May 1, 2026 · source

VerifiedCoverage

Real differentiator for users with eligible commercial coverage. Eligibility is the gating factor; if you do not have qualifying insurance, the cash-pay math does not match all-inclusive cohort competitors.

With commercial insurance and a Novo Nordisk savings card, can cost $0-$25/month via Hims.

hims.com Wegovy cost guide · captured May 1, 2026 · source

Rubric breakdown

How this is scored

Licensure

20% weight
3.0/5

Active state license, no recent disciplinary actions, no FDA enforcement.

Active 50-state telehealth licensure as a publicly-traded company with mature compliance infrastructure. Counterweight: twin dated September 9, 2025 directly to Hims & Hers Health Inc. (dba Hims and dba Hers) cited false or misleading claims on marketing. Recency is the issue here, the warning letters are eight months old at capture date and weighed against the operating-license signal.

What we verified (4)

  • Hims & Hers Health, Inc. (NYSE: HIMS) operating entity

    Business filing

    Publicly-traded under ticker HIMS; SEC filings are public. Founded 2017, IPO via SPAC merger in January 2021.

    Checked May 1, 2026

  • FDA Warning Letter to Hims & Hers Health Inc. dba Hims (CMS #716567)

    Federal enforcement

    Dated September 9, 2025. FDA cited claims like "Same active ingredient as and " and "Clinically proven ingredients" as false or misleading under sections 502(a) and 502(bb) of the FD&C Act, because drugs are not FDA-approved and cannot be marketed as equivalent to the brand-name approved products.

    Checked May 1, 2026 · source

  • FDA Warning Letter to Hims & Hers Health Inc. dba Hers (CMS #716825)

    Federal enforcement

    Companion warning letter to the Hers brand, also dated September 9, 2025, on the same - marketing claims.

    Checked May 1, 2026 · source

  • Active 50-state licensure

    State licensure

    Hims operates in all 50 states via a network of licensed independent clinicians.

    Checked May 1, 2026

Accreditation

20% weight
4.0/5

PCAB, LegitScript, NABP, USP <797> stack.

Accredited Business since February 22, 2018 with an A+ rating, the strongest BBB posture in our cohort. certification is inferred (Hims advertises on Google and Meta, which require it) but not independently confirmable on a public registry, since LegitScript does not publish a per-merchant directory.

What we verified (3)

  • BBB Accredited since February 22, 2018, A+ rating

    Accreditation

    Hims & Hers Inc. (San Francisco) is the -accredited entity. A+ is the strongest BBB rating in our cohort.

    Checked May 1, 2026 · source

  • LegitScript Healthcare Merchant Certification

    Accreditation

    Inferred from active Google and Meta advertising (which requires ), but LegitScript does not publish a public per-merchant directory we could confirm against.

    Checked May 1, 2026 · source

  • Authorized distribution for Novo Nordisk branded GLP-1

    Supply-chain authorization

    March 9, 2026 settlement with Novo Nordisk made Hims an authorized seller of branded injection, oral Wegovy pill, and . The settlement also resolved the February 2026 Novo lawsuit.

    Checked May 1, 2026 · source

Transparency

20% weight
3.5/5

CoAs, ingredient sourcing, formulation disclosure.

As a publicly-traded company, Hims has stronger baseline disclosure than private competitors (SEC filings, earnings calls, audited financials). Pricing is published on the website. Counterweight: and complaint patterns recurrently cite the membership-vs-medication billing structure as confusing, with the headline price often appearing to be all-in until users see medication billed separately.

What we verified (4)

  • Public-company SEC filings

    Financial transparency

    NYSE: HIMS. Quarterly 10-Qs and annual 10-K are public. This is unusual disclosure depth in our cohort.

    Checked May 1, 2026

  • Pricing published on hims.com weight-loss page

    Pricing transparency

    Checked May 1, 2026 · source

  • Membership separate from medication clearly disclosed

    Pricing transparency

    and complaints describe the structure as misleading: $39 first-month price is membership-only and the medication cost surfaces separately. Disclosure is technically present but the framing causes recurring confusion.

    Checked May 1, 2026 · source

  • Compounded GLP-1 program publicly wound down

    Compliance disclosure

    Per the March 2026 settlement, Hims agreed to stop advertising . Branded-only is the post-settlement model.

    Checked May 1, 2026 · source

Product quality

15% weight
3.5/5

Independent test results, recall history, supply-chain controls.

Post-settlement product mix is FDA-approved branded medication ( injection, oral Wegovy pill, ) dispensed through standard pharmaceutical supply chain, which is genuinely strong on quality assurance. Counterweight: the September 2025 on prior - marketing reflect on the company's recent track record, even though the compounded line is now wound down.

What we verified (3)

  • Branded GLP-1 supply via authorized distribution

    Sourcing

    injection, oral Wegovy pill, and dispensed through Novo Nordisk authorized distribution post March 2026 settlement.

    Checked May 1, 2026 · source

  • No FDA recalls on Hims-distributed branded GLP-1

    Recall history

    Checked May 1, 2026 · source

  • Prior compounded-marketing posture (now corrected)

    Vendor/marketing oversight

    Twin Sept 9, 2025 cited misleading marketing on then-current . The company has since wound down compounded advertising under the March 2026 settlement, but the warning letters are recent enough to weigh.

    Checked May 1, 2026 · source

Pricing

15% weight
3.0/5

Value within the category, no surprise fees, refund policy.

Membership ($39 first month, $149/mo standard) is on top of medication cost. Oral starts at $149/mo medication; injectable Wegovy is higher. With commercial insurance covering Wegovy and a Novo Nordisk savings card, effective monthly cost can drop to $0-$25 via Hims's insurance pathway. Cash-pay users on will not find a path here anymore (post-settlement, branded only) and are better served by all-inclusive specialists like TrimRx or Eden.

What we verified (3)

  • Pricing published on Hims weight-loss page

    Pricing transparency

    $39 first month, $149/mo membership thereafter; oral $149/mo medication; Wegovy injection higher.

    Checked May 1, 2026 · source

  • Insurance pathway with Novo savings card

    Coverage

    With eligible commercial insurance and a Novo Nordisk savings card, can drop to $0-$25/month via Hims.

    Checked May 1, 2026 · source

  • No undisclosed fees

    Billing complaints

    and complaints describe unauthorized charges and difficulty cancelling subscriptions. The membership-plus-medication structure is the most common point of confusion.

    Checked May 1, 2026 · source

Customer service

10% weight
3.0/5

Refund policy, support quality, complaint history.

Mixed external review picture: rates A+ with accreditation since 2018 (strong), is 3.0/5 across roughly 8,000 reviews with 28% one-star (weak). The split is real and large enough to weigh down this score. Top recurring negatives across platforms: cancellation friction, surprise charges, async-only consultations with no labs ordered before prescribing.

What we verified (4)

  • BBB A+ rating, accredited since February 22, 2018

    Complaint history

    A+ is the strongest rating in our cohort. Long-tenured accreditation is itself a positive signal.

    Checked May 1, 2026 · source

  • Trustpilot rating: 3.0/5 across roughly 8,000 reviews

    External review

    40% 5-star, 28% 1-star at capture date. The bimodal distribution is itself a signal: a large slice of users is genuinely unhappy.

    Checked May 1, 2026 · source

  • ConsumerAffairs profile

    External review

    Recurring complaint themes match : subscription billing confusion, cancellation friction, automatic refills.

    Checked May 1, 2026 · source

  • Async-only consultations, no labs before prescribing

    Care model

    Telehealth-typical: synchronous video is not standard, and labs are not ordered before issuing a prescription.

    Checked May 1, 2026

Public reviews

What we found across third-party review platforms. These are external sentiment signals, not our scoring inputs.

Trustpilot

3.0/5 across roughly 8,000 reviews. Distribution is bimodal: 40% 5-star, 28% 1-star. Negatives concentrate on cancellation friction, surprise charges, and difficulty unsubscribing. Positives concentrate on convenience and visible results.

Captured May 1, 2026Source

Better Business Bureau

Accredited since February 22, 2018; current rating A+. The complaint themes mirror (cancellation, refund processing, unauthorized charges) but the company has been responsive enough to maintain A+ accreditation, which is the strongest BBB posture in our cohort.

Captured May 1, 2026Source

ConsumerAffairs

Recurring negative themes: misleading sign-up flow, automatic refill structure, prepaid annual billing. The pattern matches rather than the complaint resolution view.

Captured May 1, 2026Source

Regulatory & legal history

FDA enforcement actions, manufacturer lawsuits, recalls, and other notable events on the public record.

  1. FDA Warning LetterSeptember 9, 2025

    FDA issued warning letter (CMS #716567) to Hims & Hers Health Inc. dba Hims, citing claims like "Same active ingredient as and " and "Clinically proven ingredients" on the - product page as false or misleading under sections 502(a) and 502(bb) of the FD&C Act. Compounded drugs are not FDA-approved and cannot be marketed as equivalent to brand-name approved products. Hims was given 15 working days to respond.

    Source
  2. FDA Warning LetterSeptember 9, 2025

    Companion (CMS #716825) to Hims & Hers Health Inc. dba Hers, on the same - marketing claims. Issued the same day.

    Source
  3. Lawsuit FiledJune 22, 2025

    Novo Nordisk terminated its April 2025 collaboration with Hims & Hers, citing concerns about Hims's continued mass compounding of and what Novo described as deceptive marketing of copycats of .

    Source
  4. SettlementMarch 9, 2026

    Novo Nordisk and Hims & Hers reached a settlement: Novo dropped its lawsuit and Hims became an authorized seller of (injection and oral pill) and . As part of the deal, Hims agreed to stop advertising medications. This resolved the prior 2025 dispute and reset the commercial relationship.

    Source

What to expect

  1. 1

    Async intake form

    10-15 min

    Online intake covering current weight, BMI, medical history, current medications, and weight-loss goals. Insurance information optional but strongly recommended for the pricing path.

  2. 2

    Clinician review + insurance check

    Same day or next business day

    Licensed clinician reviews the intake and issues a prescription if appropriate. If you submitted insurance, the eligibility check runs in parallel for the Novo savings-card pathway.

  3. 3

    Pharmacy fulfillment via authorized distribution

    3-7 days

    Approved for branded or routes through authorized pharmacy distribution. Cold-chain shipping for injections; the oral Wegovy pill ships standard.

  4. 4

    Membership auto-renewal

    Ongoing

    $39 first month auto-renews to $149/month membership. Cancellation friction is the most common complaint theme on and ; cancel through the documented in-app flow before your next billing cycle if you are stopping.

Accreditations

State pharmacy/clinic license

Verified · May 1, 2026

LegitScript Certified

Unverified · May 1, 2026 · source

Frequently asked

Is Hims & Hers legit?

Yes. Hims & Hers Health, Inc. is a publicly-traded company on the New York Stock Exchange (ticker: HIMS), -Accredited with an A+ rating since February 22, 2018 (the strongest BBB posture in our cohort), and post-March 2026 settlement is an authorized seller of branded (injection and oral pill) and from Novo Nordisk. The honest counterweights are the twin dated September 9, 2025 on prior - marketing claims (now wound down per the settlement) and the public Novo Nordisk dispute that preceded the settlement. For users with insurance covering branded Wegovy or , Hims is a credible option, especially if you specifically want the new oral Wegovy pill or value the public-company SEC disclosure as a transparency signal. Ro is the cleaner alternative given Ro avoided the 2025 FDA enforcement.

Did Hims really get an FDA warning letter?

Yes, two of them on the same day. On September 9, 2025, the FDA issued warning letters to both Hims & Hers Health Inc. dba Hims (CMS #716567) and dba Hers (CMS #716825). The agency cited marketing claims like "Same active ingredient as and " and "Clinically proven ingredients" on - product pages as false or misleading under federal law, because compounded drugs are not FDA-approved and cannot be marketed as equivalent to the brand-name approved products. Hims was given 15 working days to respond. Both letters are publicly available on the FDA website.

What happened with Hims and Novo Nordisk?

In April 2025 Novo announced a partnership making Hims an outlet for branded . In June 2025 Novo terminated the collaboration, citing Hims's continued mass compounding of and what Novo characterized as deceptive marketing. Novo later sued Hims in February 2026 over oral semaglutide. On March 9, 2026 the two companies reached a settlement: Novo dropped the lawsuit, Hims became an authorized seller of Wegovy (injection and pill) and , and Hims agreed to stop advertising compounded . The post-settlement business model is branded-only.

Is Hims BBB-accredited?

Yes. Hims & Hers Inc. (San Francisco) has been Accredited since February 22, 2018 with an A+ rating, the strongest BBB posture in our cohort. The profile is at https://www.bbb.org/us/ca/san-francisco/profile/health-and-medical-products/hims-hers-inc-1116-880029. Long-tenured A+ accreditation is itself a positive signal even though reviews are weaker.

Why is the Trustpilot score so much lower than the BBB rating?

is 3.0/5 across roughly 8,000 reviews with 28% one-star ratings, while is A+ accredited since 2018. The two platforms measure different things. BBB ratings reflect complaint resolution behavior over time, where Hims is responsive enough to maintain A+. Trustpilot reflects what individual customers post, where the most upset users dominate. Both are real signals; we weigh them both. The recurring Trustpilot negatives match BBB complaint themes (cancellation friction, surprise charges).

How much does Wegovy cost via Hims?

Cash-pay, oral starts at $149/month medication plus the $149/month membership ($39 first month). Wegovy injection is higher. With eligible commercial insurance covering Wegovy plus a Novo Nordisk savings card, effective cost can drop to $0-$25/month via Hims's insurance pathway. If you do not have qualifying insurance, the math is not as competitive as all-inclusive specialists.

Can I still get compounded semaglutide from Hims?

No, not for new patients. Per the March 2026 settlement with Novo Nordisk, Hims agreed to stop advertising medications. The post-settlement weight-loss product line is branded-only ( injection, oral Wegovy pill, ). If you specifically want compounded GLP-1, look at TrimRx or Eden instead.

How do I cancel Hims weight-loss membership?

Cancellation friction is the most common complaint theme on and . The cleanest path is to cancel through the documented in-app flow before your next billing cycle; do not let auto-renewal trigger if you are stopping. If you hit obstacles, the BBB profile shows the company does respond to formal complaints (which is part of why the A+ rating holds), so escalating in writing is a valid recourse.

Update history

Every meaningful change to this profile, with a date stamp. We don't silently re-score.

  1. May 1, 2026

    Initial published profile. Sources HEAD-checked at publish time. Score (3.4) reflects the trade-off between strong baseline signals (public-company disclosure, A+ since 2018, post-settlement branded-only supply chain) and meaningful negatives (twin Sept 2025, 3.0/5 with 28% one-star, recurring billing-friction complaints). The March 2026 Novo settlement is recent enough that we may revisit the score in a future review window.

Compare Hims & Hers head-to-head

Stuck choosing? We pick a winner per use case in the comparisons below.

vs Ro

Independent head-to-head: Ro vs Hims for Wegovy and Ozempic. Insurance pathway, BBB rating, FDA history, and real pricing compared.

See verdict

vs TrimRx

Independent head-to-head: TrimRx vs Hims for GLP-1. Cash-pay compounded specialist vs a public branded-Wegovy seller post-settlement.

See verdict

Reviewed by Designing Longevity Editorial. Last fact-checked May 1, 2026.

Spot something out of date or wrong? Let us know and we'll re-check.

Back to all providers